A Lung Health Company
In the last five years, mucus has become a main focus in treating chronic inflammatory airways diseases, such as non-cystic fibrosis bronchiectasis (NCFBE). It not only directly contributes to the vicious cycle of excess mucus secretion, chronic inflammation, and tenacious infections, but also a significant contributor to progressive declines in quality of life.
ARINA-1 has been shown to not only restore mucociliary clearance and ciliary function and expression, but also downregulate inflammation. It also has a potent secondary antibacterial mechanism that helps protect the lungs from bacterial growth. ARINA-1 restores lung health by clearing mucus, downregulating inflammation, and inhibiting bacterial growth. Individuals who have used ARINA·1 report significantly improved quality of life and decreased mucus burden.
Renovion is targeting three main indications: prevention of bronchiolitis obliterans (BOS) progression in bilateral lung transplant, non-CF bronchiectasis (NCFBE), and non-tuberculous mycobacteria-lung disease (NTM-LD). ARINA-1 is a next generation mucolytic that can
improve people’s lives and change the course of their disease.
In our target diseases, thick mucus often accumulates in the lungs and cannot be effectively cleared out of the airways, which leads to mucus plugging and difficulty breathing.